Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Foluso Fakorede, MD, interventional cardiologist, Cardiovascular Solutions of Central Mississippi, explains how he moved to rural Mississippi, the epicenter of the PAD and CLI epidemic, to open a practice to take action and reverse the glaring health disparities and that are leading to more than 400 leg amputations per day in the U.S.

Cardiologist moves to Mississippi to fight back against PAD and limit amputations

Interventional cardiologist Foluso Fakorede, MD, opened a practice in rural Mississippi, the epicenter of the PAD and CLI epidemic, to try and reverse the glaring health disparities in that region.

ACC.24 sign American College of Cardiology

ACC.24: Impella CP boosts survival for patients with STEMI-related cardiogenic shock

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said. 

ACC.24 late-breaking clinical trials

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24, the annual meeting of the American College of Cardiology (ACC), kicked off on Saturday, April 6, with a series of late-breaking clinical trials focused on testing the safety and effectiveness of new treatment strategies.

Day 1 at ACC.24: Late-breakers examine potential new heart attack, heart failure treatments

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies. 

Thickening of artery wall, reduced heart function linked to HIV

HIV carries a fourfold increase in risk of sudden cardiac death, even in asymptomatic patients.

healthcare value value-based care money dollar

Johnson & Johnson to acquire Shockwave Medical for $13.1B

The rumors, it seems, were true. Once the deal is finalized, Shockwave Medical will operate as a business unit within Johnson & Johnson MedTech.

Transcatheter pulmonary valve replacement (TPVR) with Medtronic’s self-expanding Harmony valve is both safe and effective after more than a year, according to new real-world data published in the Journal of the American College of Cardiology.[1]

TPVR with self-expanding Harmony valve associated with ‘excellent’ real-world outcomes

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR.